Nevirapin Mylan (Nevirapine)

Nevirapine, the active ingredient in Nevirapin Mylan, is a non‑nucleoside reverse transcriptase inhibitor presented as an oral tablet for oral use. It is employed in the treatment of HIV‑1 infection, typically as part of combination antiretroviral therapy in adults and children.

GNH USA supplies Nevirapin Mylan as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies, transplant centres and clinics worldwide.

Nevirapine is an NNRTI used to manage HIV‑1 infection by targeting viral replication.

HIV‑1 infection: suppresses viral load when combined with other antiretroviral agents. Prevention of mother‑to‑child transmission: reduces the risk of vertical HIV transmission when used in pregnant women as part of combination therapy. Treatment‑experienced patients: provides an alternative NNRTI option for individuals with resistance to other antiretrovirals.

Nevirapine may cause a range of adverse reactions, varying from mild to severe.

Common Side Effects: - Rash or skin irritation - Nausea or vomiting - Fatigue or weakness - Headache - Dizziness - Abdominal pain or discomfort

Serious or Rare Side Effects: - Stevens‑Johnson syndrome or toxic epidermal necrolysis - Severe hepatic failure or hepatitis - Hypersensitivity reactions with fever and eosinophilia - Neutropenia or severe anemia - Elevated bilirubin or transaminases - Life‑threatening skin reactions

When prescribing nevirapine, clinicians should observe several safety considerations.

Liver monitoring: check baseline and periodic liver function tests due to risk of hepatotoxicity. Rash assessment: inspect for skin reactions, especially during the first 8 weeks. Pregnancy risk: avoid use in pregnancy unless benefits outweigh risks, as it is Category D. Drug interaction review: evaluate concomitant medications that induce or inhibit CYP3A4. Adherence counseling: emphasize strict adherence to prevent resistance development. Store at below 25°C: keep in the original container, protect from moisture and heat.

Nevirapine interacts with several medicines through metabolic pathways.

Major Interactions (Avoid): - Rifampicin: strong CYP3A4 inducer that reduces nevirapine exposure. - Protease inhibitors boosted with ritonavir: increase nevirapine levels, raising toxicity risk. - St. John’s wort: herbal inducer that markedly lowers nevirapine concentrations. - Azole antifungals (e.g., ketoconazole): may increase nevirapine levels, leading to adverse effects.

Moderate Interactions (Monitor Closely): - Efavirenz: co‑administration may increase hepatic toxicity; monitor liver enzymes. - Hormonal contraceptives: nevirapine can reduce efficacy; advise alternative contraception. - Anticonvulsants (e.g., carbamazepine): may alter nevirapine metabolism; adjust dosing as needed.